Payment overview · 2025
General Payments
$2,214.09
27 reported records · 15 companies
Healthcare provider profile · identity verified
Scott D. Stringer, MD
Allopathic & Osteopathic Physicians|Emergency Medicine · SACRAMENTO, CA · NPI 1720196611
Verified facts
What the public records show
CMS Open Payments records show Scott D. Stringer, MD received $2,214.09 in general payments during 2025 across 27 reported records.
Amgen Inc. accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $291.66 | 13.2% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $241.57 | 10.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $240.17 | 10.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $227.55 | 10.3% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $165.53 | 7.5% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $127.93 | 5.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 5.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $122.83 | 5.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $122.31 | 5.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $121.84 | 5.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.36 | 5.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $109.02 | 4.9% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $97.81 | 4.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $72.68 | 3.3% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $26.83 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,214.09 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $240.17 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $136.21 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $127.93 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $124.64 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $122.83 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $122.31 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.64 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $121.36 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.93 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $113.99 | 4 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $113.56 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $109.02 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $73.43 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $72.68 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $69.79 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $12.23 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $12.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 126 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 22 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
185 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 844 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 562 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 534 | 115 |
| Gabapentin | Gabapentin | 423 | 106 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 364 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 355 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 348 | 101 |
| Losartan Potassium | Losartan Potassium | 343 | 99 |
| Eliquis | Apixaban | 335 | 61 |
| Potassium Chloride | Potassium Chloride | 319 | 81 |
| Furosemide | Furosemide | 313 | 86 |
| Quetiapine Fumarate | Quetiapine Fumarate | 311 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 78 |
| Metformin Hcl | Metformin Hcl | 263 | 55 |
| Mirtazapine | Mirtazapine | 231 | 56 |
| Lisinopril | Lisinopril | 227 | 58 |
| Sertraline Hcl | Sertraline Hcl | 223 | 50 |
| Donepezil Hcl | Donepezil Hcl | 209 | 34 |
| Xarelto | Rivaroxaban | 185 | 29 |
| Omeprazole | Omeprazole | 183 | 44 |
| Carvedilol | Carvedilol | 176 | 43 |
| Spironolactone | Spironolactone | 164 | 41 |
| Trazodone Hcl | Trazodone Hcl | 162 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 158 | 111 |
| Divalproex Sodium | Divalproex Sodium | 152 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 49 |
| Simvastatin | Simvastatin | 135 | 42 |
| Irbesartan | Irbesartan | 133 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 25 |
| Jardiance | Empagliflozin | 126 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 54 |
| Cefuroxime | Cefuroxime Axetil | 116 | 55 |
| Montelukast Sodium | Montelukast Sodium | 113 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 29 |
| Famotidine | Famotidine | 108 | 26 |
| Olanzapine | Olanzapine | 107 | 13 |
| Buspirone Hcl | Buspirone Hcl | 105 | 26 |
| Allopurinol | Allopurinol | 104 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 22 |
| Tramadol Hcl | Tramadol Hcl | 97 | 36 |
| Farxiga | Dapagliflozin Propanediol | 95 | 21 |
| Alprazolam | Alprazolam | 94 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 19 |
| Finasteride | Finasteride | 89 | 24 |
| Alendronate Sodium | Alendronate Sodium | 87 | 26 |
| Memantine Hcl | Memantine Hcl | 86 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 38 |
| Diazepam | Diazepam | 80 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 29 |
| Meloxicam | Meloxicam | 76 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 75 | 13 |
| Latanoprost | Latanoprost | 74 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 14 |
| Benazepril Hcl | Benazepril Hcl | 71 | 13 |
| Pregabalin | Pregabalin | 63 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 13 |
| Ozempic | Semaglutide | 60 | 15 |
| Ezetimibe | Ezetimibe | 59 | 12 |
| Torsemide | Torsemide | 58 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 18 |
| Lorazepam | Lorazepam | 55 | 15 |
| Mounjaro | Tirzepatide | 55 | 11 |
| Prednisone | Prednisone | 55 | 25 |
| Midodrine Hcl | Midodrine Hcl | 54 | 22 |
| Bupropion Xl | Bupropion Hcl | 50 | 15 |
| Levetiracetam | Levetiracetam | 50 | 12 |
| Metformin Hcl Er | Metformin Hcl | 50 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 32 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Celecoxib | Celecoxib | 43 | 11 |
| Telmisartan | Telmisartan | 43 | suppressed |
| Ketoconazole | Ketoconazole | 42 | 15 |
| Lidocaine | Lidocaine | 41 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 12 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 39 | suppressed |
| Lactulose | Lactulose | 39 | 16 |
| Nystatin | Nystatin | 38 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 37 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Nystop | Nystatin | 36 | 12 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 11 |
| Risperidone | Risperidone | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 32 | 18 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Premarin | Estrogens, Conjugated | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 14 |
| Atenolol | Atenolol | 30 | suppressed |
| Cephalexin | Cephalexin | 30 | 24 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Insulin Lispro | Insulin Lispro | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Humalog | Insulin Lispro | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Tobramycin | Tobramycin | 26 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Colchicine | Colchicine | 25 | 13 |
| Topiramate | Topiramate | 25 | suppressed |
| Humulin R | Insulin Regular, Human | 24 | 15 |
| Tramadol Hcl Er | Tramadol Hcl | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 19 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Enulose | Lactulose | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 12 |
| Meclizine Hcl | Meclizine Hcl | 19 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Armour Thyroid | Thyroid,pork | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Galantamine Er | Galantamine Hbr | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Buprenorphine | Buprenorphine | 17 | suppressed |
| Ertapenem | Ertapenem Sodium | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Lamotrigine Er | Lamotrigine | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Levocarnitine | Levocarnitine | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | 11 |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Cordran | Flurandrenolide | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,214.09 · 27 records | Amgen Inc. | AIRSUPRA, BREZTRI, Bimzelx, Dexcom G6 Transmitter, EVENITY, JARDIANCE, KRYSTEXXA, Korlym, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, REPATHA, RINVOQ, SKYRIZI, TAVNEOS, TREMFYA, TZIELD, ZENPEP, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error